Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
10.30
Dollar change
-0.17
Percentage change
-1.62
%
IndexRUT P/E- EPS (ttm)-1.74 Insider Own7.46% Shs Outstand70.12M Perf Week-4.19%
Market Cap733.57M Forward P/E- EPS next Y-0.10 Insider Trans-0.76% Shs Float65.91M Perf Month-20.16%
Income-118.67M PEG- EPS next Q-0.32 Inst Own92.57% Short Float6.00% Perf Quarter-3.56%
Sales76.01M P/S9.65 EPS this Y43.22% Inst Trans-0.52% Short Ratio6.96 Perf Half Y61.70%
Book/sh6.57 P/B1.57 EPS next Y89.35% ROA-19.30% Short Interest3.96M Perf Year27.16%
Cash/sh5.26 P/C1.96 EPS next 5Y11.00% ROE-24.78% 52W Range6.01 - 13.14 Perf YTD-0.87%
Dividend Est.- P/FCF- EPS past 5Y-6.52% ROI-24.36% 52W High-21.61% Beta1.13
Dividend TTM- Quick Ratio7.41 Sales past 5Y35.24% Gross Margin77.23% 52W Low71.24% ATR (14)0.44
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-197.79% Oper. Margin-181.62% RSI (14)36.25 Volatility2.56% 4.35%
Employees277 Debt/Eq0.06 Sales Y/Y TTM-81.57% Profit Margin-156.13% Recom1.86 Target Price13.60
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-104.40% Payout0.00% Rel Volume0.70 Prev Close10.47
Sales Surprise-4.18% EPS Surprise51.77% Sales Q/Q-95.79% EarningsMar 06 AMC Avg Volume568.61K Price10.30
SMA20-8.20% SMA50-7.74% SMA20017.79% Trades Volume398,746 Change-1.62%
Date Action Analyst Rating Change Price Target Change
Mar-21-23Resumed Wells Fargo Overweight $12
Jan-04-23Reiterated H.C. Wainwright Neutral $10 → $8
Dec-20-22Upgrade Jefferies Hold → Buy $7.70 → $11
Nov-01-22Downgrade H.C. Wainwright Buy → Neutral $40 → $8
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $8
Oct-04-22Resumed Wells Fargo Overweight $45 → $9
May-05-22Upgrade Guggenheim Neutral → Buy $14
Mar-15-22Initiated Evercore ISI Outperform $15
Dec-10-21Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21Resumed Guggenheim Neutral
Today 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
06:39AM Loading…
Mar-07-24 06:39AM
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
12:00PM Loading…
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
08:30AM Loading…
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
04:15PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Jun-27-22 08:30AM
Jun-10-22 09:57AM
09:15AM
May-27-22 09:57AM
05:30AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Galbraith KennethChair & CEOJan 08 '24Sale11.225,70663,99623,762Jan 08 06:23 PM
Moore Paul AndrewChief Scientific OfficerJan 08 '24Sale11.222,33926,2337,367Jan 08 06:01 PM
Astle ChristopherSVP & Chief Financial OfficerJan 08 '24Sale11.221,43116,0506,503Jan 08 06:14 PM
Moore Paul AndrewChief Scientific OfficerJan 05 '24Option Exercise0.0017,166017,166Jan 08 06:01 PM
Galbraith KennethChair & CEOJan 05 '24Option Exercise0.0047,666047,666Jan 08 06:23 PM
Astle ChristopherSVP & Chief Financial OfficerJan 05 '24Option Exercise0.0010,500012,497Jan 08 06:14 PM
Galbraith KennethChair & CEOJan 05 '24Sale10.6518,198193,84929,468Jan 08 06:23 PM
Moore Paul AndrewChief Scientific OfficerJan 05 '24Sale10.657,46079,4659,706Jan 08 06:01 PM
Astle ChristopherSVP & Chief Financial OfficerJan 05 '24Sale10.654,56348,6067,934Jan 08 06:14 PM
Astle ChristopherSVP & Chief Financial OfficerDec 11 '23Option Exercise0.001,55002,883Dec 11 08:00 PM
Astle ChristopherSVP & Chief Financial OfficerDec 11 '23Sale9.138868,0891,997Dec 11 08:00 PM
EcoR1 Capital, LLC10% OwnerJun 16 '23Buy8.123,350,00027,202,00013,437,473Jun 21 04:04 PM